CalciMedica公司今日宣布，已与美国食品药品监督管理局（FDA）就旗下候选药物Auxora在治疗急性胰腺炎方面的2B期临床试验设计达成一致。这意味着，该公司在推进这一关键疗法的道路上迈出了决定性一步。
更为重要的是，此次监管沟通不仅明确了试验路径，还首次为急性胰腺炎这一疾病领域识别出了潜在的注册终点。这些终点被视为评估新药疗效并最终获得上市批准的关键衡量标准——对于长期以来缺乏有效治疗手段的急性胰腺炎患者而言，这无疑是一缕曙光。Auxora作为一种针对急性炎症反应的创新疗法，其2B期试验的顺利推进，将为后续临床开发铺平道路。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.